Reuters logo
BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan
July 13, 2017 / 12:24 PM / 2 months ago

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

July 13 (Reuters) - Radius Health Inc;

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health Inc - ‍radius to receive upfront and milestone payments, royalties, and an option for co-promotion​

* Radius Health - ‍Teijin granted a right of reference to Radius regulatory data

* Radius Health - co maintains full global rights to its development program for Abaloparatide-Transdermal which is not part of agreement with Teijin

* Radius Health - ‍Teijin also granted use of Radius intellectual property for development, manufacture and commercialization of abaloparatide-sc for Japan​

* Radius Health Inc - ‍collaboration agreement provides Teijin with right to manufacture abaloparatide-sc for commercial supply in Japan​

* Radius Health-‍Teijin conducting, funding Japanese phase 3 development program; parties may further collaborate in future in new indications for product​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below